Global Briefs: Incyte, CDC, Bavarian Nordic & More
A roundup of news from Incyte, the CDC, Bavarian Nordic, and Pierre Fabre Laboratories. Highlights below.
Leadership Changes
* Incyte Names New CEO
Regulatory News
* Revamped CDC Vaccine Panel Holds First Meeting
General
* Bavarian Nordic To Sell Priority Review Voucher
* Pierre Fabre Laboratories Opens US Office
Leadership Changes
Incyte Names New CEO
Incyte, a Wilmington, Delaware-based bio/pharmaceutical company, has announced that the company’s Board of Directors has unanimously appointed Bill Meury, former CEO of Anthos Therapeutics, a Cambridge, Massachusetts-based bio/pharmaceutical company, as President and CEO and a member of the company’s Board of Directors, succeeding Hervé Hoppenot, who is retiring from his role as Incyte’s CEO after 11 years, effective immediately (as reported on June 26, 2025).
Meury most recently served as CEO of Anthos Therapeutics, where he scaled the company for its next stage of growth. Prior to that, he was CEO of Karuna Therapeutics, a Boston-based bio/pharmaceutical company, leading its transition into a fully integrated R&D and commercial organization. Before Karuna, Meury spent more than two decades at Allergan, serving as Chief Commercial Officer and managing a global business with 50 products, $16 billion in revenues, and approximately 8,000 employees across a range of therapeutic areas.
Hoppenot will serve as an advisor to the CEO and will remain as a member of the Board through the end of the year (2025) to ensure a smooth transition. In addition, Lead Independent Director Julian Baker, current Managing Partner of Baker Bros. Advisors, has been elected Chairman of the Board of Directors.
Source: Incyte
Regulatory News
Revamped CDC Vaccine Panel Holds First Meeting
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) held its first meeting following a revamping of the committee earlier this month (June 2025) by US Health and Human Services Department Secretary Robert F. Kennedy, Jr. The ACIP comprises medical and public health experts that advise the CDC on the safety, effectiveness, and clinical necessity of vaccines. Earlier this month (June 2025), HHS Secretary Kennedy removed the 17 sitting members of ACIP and replaced them with eight new members. The meeting was held at CDC headquarters in Atlanta, Georgia, on June 25 and June 26, 2025.
Source: Centers for Disease Control and Prevention
General
Bavarian Nordic To Sell Priority Review Voucher
Bavarian Nordic, a Hellerup (near Copenhagen), Denmark-based vaccines company, has announced that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of $160 million.
Bavarian Nordic was awarded the PRV in February 2025, following the approval by the US Food and Drug Administration of its chikungunya vaccine, Vimkunya, for prevention of disease caused by chikungunya virus in people 12 years of age and older.
Pursuant to a license agreement assumed upon acquisition of the chikungunya vaccine in 2023, the National Institutes of Health (NIH) in the US will receive 20% of the gross proceeds from the sale of the PRV. The transaction remains subject to customary closing conditions, including antitrust review, which is expected to occur in the third quarter of 2025.
Source: Bavarian Nordic
Pierre Fabre Laboratories Opens US Office
Pierre Fabre Laboratories, a French bio/pharmaceutical company, has announced the inauguration of its new US office located in Secaucus, New Jersey, which will house its dermo-cosmetics and medical care subsidiaries.
Source: Pierre Fabre Laboratories
